E-viri
Recenzirano
Odprti dostop
-
Ansell, Stephen M.; Radford, John; Connors, Joseph M.; Długosz-Danecka, Monika; Kim, Won-Seog; Gallamini, Andrea; Ramchandren, Radhakrishnan; Friedberg, Jonathan W.; Advani, Ranjana; Hutchings, Martin; Evens, Andrew M.; Smolewski, Piotr; Savage, Kerry J.; Bartlett, Nancy L.; Eom, Hyeon-Seok; Abramson, Jeremy S.; Dong, Cassie; Campana, Frank; Fenton, Keenan; Puhlmann, Markus; Straus, David J.
The New England journal of medicine, 07/2022, Letnik: 387, Številka: 4Journal Article
The replacement of bleomycin with the immune drug conjugate brentuximab vedotin in the first-line chemotherapy regimen for advanced Hodgkin’s lymphoma prolonged both progression-free and overall survival.
